Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DRTECH Corporation (214680.KQ)
Seongnam-si, KR
DRTECH Corporation focuses on the development and global distribution of flat-panel X-ray detectors for digital radiography, serving markets both within South Korea and abroad. Their extensive product line includes detectors customized for diverse applications such as general medical imaging, mammography, dynamic studies, dental diagnostics, veterinary care, and industrial inspections. Furthermore, the company offers integrated imaging solutions, which incorporate specialized user interface software, dual-energy X-ray capabilities, artificial intelligence-powered image processing, advanced image reconstruction techniques, and AI-based Computer-Aided Detection (CAD). DRTECH also provides complete radiography, mammography, and C-arm systems. Founded in 2000, the company's headquarters are located in Seongnam-si, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.60% | -15.49% | -25.32% | -28.94% | -29.23% | -32.59% | -22.25% | -56.07% | -18.68% | -39.49% | -39.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+19.2% ★ Q1'26: +25.5% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+45.7% ★ Q1'26: +91.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-33.9% Q1'26: -4.8% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%-12.0% Q1'26: +46.5% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%-10.2% Q1'26: +43.4% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+129.6% Q1'26: -100.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-30.78× Q1'26: 1.49× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
92.44B
est: 103.40B (-10.6%)
|
97.56B
est: 108.10B (-9.8%)
|
116.30B
est: 130.50B (-10.9%)
|
175.00B
175.00B – 175.00B
+34.1% YoY
|
| EBITDA |
9.10B
est: 4.93B (+84.7%)
|
-4.39B
est: 5.33B (-182.3%)
|
-2.87B
est: 6.43B (-144.6%)
|
8.63B
8.63B – 8.63B
+34.1% YoY
|
| EBIT |
1.12B
est: -3.80B (+129.6%)
|
-14.36B
est: -4.09B (-251.3%)
|
-13.93B
est: -4.93B (-182.3%)
|
-6.62B
-6.62B – -6.62B
-34.1% YoY
|
| Net Income |
-2.25B
est: 2.70B (-183.2%)
|
-19.29B
est: -298.97M (-6,352.0%)
|
-24.03B
est: 1.64B (-1,561.2%)
|
9.19B
9.19B – 9.19B
+459.1% YoY
|
| SGA |
11.27B
est: 11.62B (-3.1%)
|
11.71B
est: 15.92B (-26.5%)
|
32.39B
est: 19.22B (+68.5%)
|
25.77B
25.77B – 25.77B
+34.1% YoY
|
| EPS |
-34.01
est: 83.00 (-141.0%)
|
-592.49
est: -4.00 (-14,712.3%)
|
-321.47
est: 22.00 (-1,561.2%)
|
123.00
123.00 – 123.00
+459.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 18.7K | 0.46% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 34.5K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 27.8K | 0.28% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 12.0K | 0.39% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 34.89 | 0.56% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Beomjin Moon | Senior Executive VP, Head of New Business Development Division & Executive Director | — | male |
| Cheol-woo Shin | COO, Head of Medical Business Development Division & Executive Director | — | male |
| Kilsoo Lee | Chief Financial Officer, Head of Corporate Planning & Executive Director | — | male |
| Seong-Hyun An | Chief Executive Officer & Executive Director | — | male |
| Soo Chul Park | Senior EVice President, Head of Global Sales Division & Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 214680.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
